Bi -institutional Safety Analysis of Combining Radiotherapy and Enfortumab Vedotin in Advanced Urothelial Cancer

被引：0
|
作者：
Soni, Y. S. [1 ]
Lock, D. [2 ]
Ballas, L. K. [3 ]
Hwang, L. [2 ]
Cole, S. [4 ]
D'Souza, A. [5 ]
Zhang, T. [4 ]
Garant, A. [1 ]
Yang, D. X. [1 ]
Arafat, W. [4 ]
Desai, N. B. [1 ]
机构：
[1] Univ Texas Southwestern Med Ctr, Dept Radiat Oncol, Dallas, TX USA
[2] LAC USC Med Ctr, Dept Radiat Oncol, Los Angeles, CA USA
[3] Cedars Sinai Med Ctr, Dept Radiat Oncol, Los Angeles, CA USA
[4] Univ Texas Southwestern Med Ctr, Dept Hematol & Oncol, Dallas, TX USA
[5] LAC USC Med Ctr, Dept Hematol & Oncol, Los Angeles, CA USA
来源：
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2024年 / 120卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
222
引用
收藏
页码：S74 / S75
页数：2
相关论文
共 50 条
  • [1] Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer
    Powles, T.
    Valderrama, B. P.
    Gupta, S.
    Bedke, J.
    Kikuchi, E.
    Hoffman-Censits, J.
    Iyer, G.
    Vulsteke, C.
    Park, S. H.
    Shin, S. J.
    Castellano, D.
    Fornarini, G.
    Li, J. R.
    Guemues, M.
    Mar, N.
    Loriot, Y.
    Flechon, A.
    Duran, I
    Drakaki, A.
    Narayanan, S.
    Yu, X.
    Gorla, S.
    Moreno, B. Homet
    van der Heijden, M. S.
    NEW ENGLAND JOURNAL OF MEDICINE, 2024, 390 (10): : 875 - 888
  • [2] Enfortumab Vedotin in Advanced Urothelial Carcinoma
    Petrylak, Daniel P.
    Powles, Thomas
    Rosenberg, Jonathan E.
    NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (01): : 93 - 94
  • [3] Enfortumab Vedotin in urothelial cancer
    Alt, Marie
    Stecca, Carlos
    Tobin, Swanee
    Jiang, Di Maria
    Sridhar, Srikala S.
    THERAPEUTIC ADVANCES IN UROLOGY, 2020, 12
  • [4] Re: Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer
    Catalano, Martina
    Santoni, Matteo
    Roviello, Giandomenico
    EUROPEAN UROLOGY, 2024, 86 (03) : 283 - 283
  • [5] Enfortumab Vedotin Plus Pembrolizumab in Previously Untreated Advanced Urothelial Cancer
    Hoimes, Christopher J.
    Flaig, Thomas W.
    Milowsky, Matthew, I
    Friedlander, Terence W.
    Bilen, Mehmet Asim
    Gupta, Shilpa
    Srinivas, Sandy
    Merchan, Jaime R.
    McKay, Rana R.
    Petrylak, Daniel P.
    Sasse, Carolyn
    Moreno, Blanca Homet
    Yu, Yao
    Carret, Anne-Sophie
    Rosenberg, Jonathan E.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (01) : 22 - +
  • [6] Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma
    Powles, Thomas
    Rosenberg, Jonathan E.
    Sonpavde, Guru P.
    Loriot, Yohann
    Duran, Ignacio
    Lee, Jae-Lyun
    Matsubara, Nobuaki
    Vulsteke, Christof
    Castellano, Daniel
    Wu, Chunzhang
    Campbell, Mary
    Matsangou, Maria
    Petrylak, Daniel P.
    NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (12): : 1125 - 1135
  • [7] Pembrolizumab plus enfortumab vedotin in urothelial cancer
    Santoni, Matteo
    Takeshita, Hideki
    Massari, Francesco
    Bamias, Aristotelis
    Cerbone, Linda
    Fiala, Ondrej
    Mollica, Veronica
    Buti, Sebastiano
    Santoni, Angela
    Bellmunt, Joaquim
    NATURE REVIEWS UROLOGY, 2024, 21 (07) : 387 - 388
  • [8] Efficacy and safety of enfortumab vedotin in the treatment of advanced urothelial carcinoma: a systematic review and meta-analysis
    Wang, Leibo
    Shi, Guanyu
    Zhao, Guoqiang
    He, Wei
    Cen, Zhuangding
    Xu, Feng
    ANTI-CANCER DRUGS, 2023, 34 (04) : 473 - 478
  • [9] Targeted Treatment of Locally Advanced and Metastatic Urothelial Cancer: Enfortumab Vedotin in Context
    Hoffman-Censits, Jean
    Maldonado, Laneisha
    ONCOTARGETS AND THERAPY, 2022, 15 : 1519 - 1529
  • [10] Efficacy of enfortumab vedotin in populations of interest among patients with advanced urothelial cancer
    Koshkin, V. S.
    Sun, Y.
    Osterman, C. K.
    Natesan, D.
    Su, C.
    Lemke, E.
    Khaki, A. R.
    Johnson, A.
    Owens, X.
    Park, J. J.
    Basu, A.
    Barata, P. M. Coelho
    Davis, N.
    Grivas, P.
    Milowsky, M.
    Kilari, D.
    Alva, A.
    ANNALS OF ONCOLOGY, 2020, 31 : S594 - S594
12345